Facile one-pot synthesis of hybrid compounds based on decavanadate showing water oxidation activity

Functionalization of decavanadate anion by coordination to cobalt(II): Binding to proteins, cytotoxicity, and water oxidation catalysis

A series of five decavanadates (V₁₀) using a simple, one-pot synthesis, adhering to the model template: transition metal ion - decavanadate - ligands:(Hnicotinamide)₂{[Co(H₂O)₃(nicotinamide)₂]₂[μ-V₁₀O₂₈]}.6H₂O (1), {[Co(H₂O)₄(isonicotinamide)₂]₃}V₁₀O₂₈·4H₂O (2), {[Co(H₂O)₄]₂[Co(H₂O)₂(μ-pyrazinamide)₂][μ-V₁₀O₂₈]}·4H₂O (3) {[Co(H₂O)₄(μ-pyrazinamide)]₃.V₁₀O₂₈}·4H₂O (4), and (NH₄)₂{[Ni(H₂O)₄(2-hydroxyethylpyridine)]₂}V₁₀O₂₈·2H₂O (5) was synthesized. X-ray analysis reveals that 1 and 3 are decavanadato complexes, while 2, 4 and 5 are decavanadate complex salts. Moreover, 3 is the first example of a polymeric decavanadato complex, employing direct coordination with the metal center and the organic ligand, in toto. From the solution studies using ⁵¹V NMR spectroscopy, it was decoded that 1 and 3 stay stable in the model buffer solution and aqueous media. Binding to model proteins, cytotoxicity and water oxidation catalysis (WOC) was studied primarily for 1 and 3 and concluded that neither 1 nor 3 have an interaction with the model proteins thaumatin, lysozyme and proteinase K, because of the presence of the organic ligands in the Co(II) center, any further interplay with the proteins was blocked. Cytotoxicity studies reveal that 1 is 40% less toxic (0.05 mM) and 26% less toxic (0.1 mM) than the uncoordinated V₁₀ with human cell lines A549 and HeLa respectively. In WOC, 1 performed superior activity, by evolving 143.37 nmol of O₂ which is 700% (9-fold) increase than the uncoordinated V₁₀.

Tris(2-Pyridylmethylamine)V(O)2 Complexes as Counter Ions of Diprotonated Decavanadate Anion: Potential Antineoplastic Activity

The synthesis and theoretical-experimental characterization of a novel diprotanated decavanadate is presented here due to our search for novel anticancer metallodrugs. Tris(2-pyridylmethyl)amine (TPMA), which is also known to have anticancer activity in osteosarcoma cell lines, was introduced as a possible cationic species that could act as a counterpart for the decavanadate anion. However, the isolated compound contains the previously reported vanadium (V) dioxido-tpma moieties, and the decavanadate anion appears to be diprotonated. The structural characterization of the compound was performed by infrared spectroscopy and single-crystal X-ray diffraction. In addition, DFT calculations were used to analyze the reactive sites involved in the donor-acceptor interactions from the molecular electrostatic potential maps. The level of theory mPW1PW91/6–31G(d)-LANL2DZ and ECP = LANL2DZ for the V atom was used. These insights about the compounds’ main interactions were supported by analyzing the noncovalent interactions utilizing the AIM and Hirshfeld surfaces approach. Molecular docking studies with small RNA fragments were used to assess the hypothesis that decavanadate’s anticancer activity could be attributed to its interaction with lncRNA molecules. Thus, a combination of three potentially beneficial components could be evaluated in various cancer cell lines.